
John Raymond Zalcberg, PhD, MBBS, discusses the rationale for intra-patient dose escalation with ripretinib, as was examined in the phase 3 INVICTUS trial in patients with advanced gastrointestinal stromal tumors.

Your AI-Trained Oncology Knowledge Connection!


John Raymond Zalcberg, PhD, MBBS, discusses the rationale for intra-patient dose escalation with ripretinib, as was examined in the phase 3 INVICTUS trial in patients with advanced gastrointestinal stromal tumors.

John Raymond Zalcberg, discusses the efficacy of intra-patient dose escalation with ripretinib in patients with advanced gastrointestinal stromal tumors, as demonstrated in an analysis of the phase 3 INVICTUS trial.

John Zalcberg, PhD, OAM, discusses the approval of avapritinib in gastrointestinal stromal tumor.

John Zalcberg, PhD, OAM, discusses the role of Gastrointestinal Cancer in advanced gastrointestinal stromal tumor.

John Zalcberg, PhD, OAM, discusses the management of patients with gastrointestinal stromal tumor.

John Zalcberg, PhD, OAM, discusses updated results from the phase 3 INVICTUS trial in advanced gastrointestinal stromal tumor.

Published: September 20th 2020 | Updated: